# For its 30th PCC anniversary, Insilico Medicine nominated ISM0387, the first UAE-based preclinical candidate.

*biotech · news · 2026-04-24 · The Manila Times*

## Key points

- Insilico Medicine nominated ISM0387, the UAE's first locally discovered AI-designed preclinical drug candidate.
- ISM0387 is an MTA-cooperative PRMT5 inhibitor optimized for brain penetration and glioblastoma treatment.
- The full discovery process for ISM0387, from molecular design to nomination, was conducted within the UAE in under 12 months.
- Using Chemistry42 and 40+ AI models, Insilico discovered and optimized ISM0387 by screening 90 novel compounds, completing lead discovery in six months.
- Enhanced blood-brain barrier penetration and robust efficacy were confirmed for ISM0387 in cancer models, supporting future clinical potential.

**Companies:** Insilico Medicine
**Countries:** UAE

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/24/tmt-newswire/pr-newswire/generative-ai-leap-insilico-medicine-nominates-first-preclinical-candidate-in-the-uae/2328178)

---

Canonical: https://newsio.io/n/f5289f94-4fff-4079-843d-3edf0c1b563e/for-its-30th-pcc-anniversary-insilico-medicine-nominated-ism0387-the-first-uae-b
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works